AU757973B2 - Desmethylolanzapine compositions and methods - Google Patents

Desmethylolanzapine compositions and methods Download PDF

Info

Publication number
AU757973B2
AU757973B2 AU17416/00A AU1741600A AU757973B2 AU 757973 B2 AU757973 B2 AU 757973B2 AU 17416/00 A AU17416/00 A AU 17416/00A AU 1741600 A AU1741600 A AU 1741600A AU 757973 B2 AU757973 B2 AU 757973B2
Authority
AU
Australia
Prior art keywords
desmethylolanzapine
disorder
pharmaceutically acceptable
acceptable salt
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU17416/00A
Other languages
English (en)
Other versions
AU1741600A (en
Inventor
William E. Yelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AU1741600A publication Critical patent/AU1741600A/en
Application granted granted Critical
Publication of AU757973B2 publication Critical patent/AU757973B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
AU17416/00A 1998-11-23 1999-11-22 Desmethylolanzapine compositions and methods Ceased AU757973B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10958498P 1998-11-23 1998-11-23
US60/109584 1998-11-23
PCT/US1999/027647 WO2000030650A1 (en) 1998-11-23 1999-11-22 Desmethylolanzapine compositions and methods

Publications (2)

Publication Number Publication Date
AU1741600A AU1741600A (en) 2000-06-13
AU757973B2 true AU757973B2 (en) 2003-03-13

Family

ID=22328453

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17416/00A Ceased AU757973B2 (en) 1998-11-23 1999-11-22 Desmethylolanzapine compositions and methods

Country Status (10)

Country Link
US (2) US6348455B1 (https=)
EP (1) EP1133300B1 (https=)
JP (1) JP2002530341A (https=)
AT (1) ATE286398T1 (https=)
AU (1) AU757973B2 (https=)
CA (1) CA2351718A1 (https=)
DE (1) DE69923081T2 (https=)
ES (1) ES2237188T3 (https=)
PT (1) PT1133300E (https=)
WO (1) WO2000030650A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
PL199016B1 (pl) 2002-06-20 2008-08-29 Adamed Sp Z Oo Sposób wytwarzania olanzapiny
US6831077B2 (en) * 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
CA2529857A1 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
KR100842694B1 (ko) 2002-12-27 2008-07-01 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
US7763660B2 (en) * 2003-02-05 2010-07-27 The University Of Vermont And State Agricultural College Inhibitors of Candida albicans
PL198589B1 (pl) 2004-11-22 2008-06-30 Adamed Sp Z Oo Sposób wytwarzania N-demetyloolanzapiny
WO2006081327A2 (en) * 2005-01-25 2006-08-03 University Of Vermont And State Agricultural College Small molecules that reduce fungal growth
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
JP2010518023A (ja) * 2007-02-01 2010-05-27 アラン アイ． グリーン ドーパミンＤ２受容体遮断剤とノルエピネフリン再取り込み阻害剤およびノルエピネフリンα２受容体遮断剤との組み合わせ

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US4590213A (en) * 1983-04-08 1986-05-20 Eli Lilly And Company Anti-anxiety method
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5627178A (en) 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
JPH11512705A (ja) 1995-09-29 1999-11-02 イーライ・リリー・アンド・カンパニー チック症を処置する方法
CA2240836A1 (en) 1995-12-21 1997-07-03 Pierre Van Tran Method for treating dermatitis
HUP9903684A3 (en) 1995-12-22 2001-12-28 Lilly Co Eli Use of olanzapine for the preparation of pharmaceutical compositions treating depression
HUP9903679A3 (en) 1996-03-11 2001-10-29 Lilly Co Eli Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder
KR19990087714A (ko) * 1996-03-11 1999-12-27 피터 지. 스트링거 물질 남용의 치료 방법
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
TR199801798T2 (xx) * 1996-03-11 1998-12-21 Eli Lilly And Company Otizm tedavisi.
GB9615767D0 (en) 1996-07-26 1996-09-04 Smithkline Beecham Plc Novel treatment

Also Published As

Publication number Publication date
JP2002530341A (ja) 2002-09-17
ES2237188T3 (es) 2005-07-16
EP1133300B1 (en) 2005-01-05
CA2351718A1 (en) 2000-06-02
US20020082251A1 (en) 2002-06-27
ATE286398T1 (de) 2005-01-15
DE69923081T2 (de) 2005-12-08
WO2000030650A1 (en) 2000-06-02
AU1741600A (en) 2000-06-13
PT1133300E (pt) 2005-04-29
EP1133300A1 (en) 2001-09-19
DE69923081D1 (de) 2005-02-10
US6468997B2 (en) 2002-10-22
US6348455B1 (en) 2002-02-19

Similar Documents

Publication Publication Date Title
TWI294779B (en) Use of optically pure (s,s)-reboxetine in the manufacture of a medicament for the treatment or prevention of peripheral neuropathy
AU756468B2 (en) Combination therapy for treatment of bipolar disorders
US6121259A (en) Olanzapine-N-oxide compositions and methods
AU757973B2 (en) Desmethylolanzapine compositions and methods
AU757874B2 (en) 2-hydroxymethylolanzapine compositions and methods
ZA200006815B (en) Combination therapy for treatment of refractory depression.
WO2015089111A1 (en) Novel methods
KR20040030788A (ko) 요실금 치료를 위한 아릴(또는 헤테로아릴)아졸릴카르비놀 유도체
CZ295776B6 (cs) Opticky čistý (+)-norcisaprid pro léčení gastroesofageálního refluxu
CN101472571B (zh) 毒蕈碱型受体m1拮抗剂在制备治疗心理学病况药物中的应用
PL197981B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
PL197982B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
PL197984B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)